Christensen, O. & Christensen, E. (1988) Fat consumption and schizophrenia. Acta Psychiatrica Scandinavica, 78, 587–591.
Connor, W. E., De Francesco, C. A. & Connor, S. L. (1993) N3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Annals of the New York Academy of Science, 683, 16–34.
Edwards, R., Peet, M., Shay, J.
et al (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders, 48, 149–155.
Emsley, R. A., Myburgh, C. C., Oosthuizen, P. P.
et al (2002) Omega-3 fatty acid and schizophrenia: a randomised trial of ethyl-eicosapentaenoic acid (ethyl-EPA) versus placebo as add-on treatment. Schizophrenia Research, 53, 9.
Fenton, W. S., Hibbeln, J. & Knable, M. (2000) Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry, 47, 8–21.
Fenton, W. S., Dickerson, F., Boronow, J.
et al (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry, 158, 2071–2074.
Henderson, D. C., Cagliero, E., Gray, C.
et al (2000) Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five year naturalistic study. American Journal of Psychiatry, 157, 975–981.
Hibbeln, J. R. (1998) Fish consumption and major depression. Lancet, 352, 71–72.
Hibbeln, J. R. (2002) Seafood consumption, the DHA content of mother's milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. Journal of Affective Disorders, in press.
Kay, S. R., Fiszbein, A & Opler, L. A. (1987) The positive and negavite syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.
Keshavan, M. S., Stanley, J. A. & Pettegrew, J. W. (2000) Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings – Part II. Biological Psychiatry, 48, 369–380.
Marangell, L. B., Zboyan, H. A., Cress, K. K.
et al (2000) A double-blind placebo-controlled study of decosahaexanoic acid in the treatment of depression. Inform, 11, S78.
Mellor, J. E., Laugharne, J. D. & Peet, M. (1995) Schizophrenic symptoms and dietary intake of n3 fatty acids. Schizophrenia Research, 18, 85–86.
Nemets, B., Stahl, Z. & Belmaker, R. H. (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry, 159, 477–479.
Oken, R. J. & Schulzer, M. (1999) At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophrenia Bulletin, 25, 625–638.
Peet, M. & Horrobin, D. F. (2001) A dose-ranging study of ethyl-eicosapentonoate in treatment-unresponsive depression. Journal of Psychopharmacology, 15 (Suppl.), A12.
Peet, M. & Horrobin, D. F. (2002) A dose-ranging exploratory study of the effects of ethyl-eicosaepentonate in patients with persistent schizophrenic symptoms. Journal of Pyschiatric Research, 36, 7–18.
Peet, M., Laugharne, J. D., Horrobin, D. F.
et al (1994) Arachidonic acid: a common link in the biology of schizophrenia?
Archives of General Psychiatry, 51, 665–666.
Peet, M., Laugharne, J. D., Rangarajan, N.
et al (1995) Depleted red cell membrane essential fatty acids in drug treated schizophrenic patients. Journal of Psychiatric Research, 29, 227–232.
Peet, M., Brind, J., Ramchand, C. N.
et al (2001) Two double blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research, 49, 243–251.
Penninx, B. W., Beekman, A. T., Horig, A.
et al (2001) Depression and cardiac mortality: results from a community based longitudinal study. Archives of General Psychiatry, 58, 229–230.
Puri, B. K., Richardson, A. J., Horrobin, D. F.
et al (2000) Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neural membrane phospholipid turnover and structural brain changes. International Journal of Clinical Practice, 54, 57–63.
Ross, B. M., Turenne, S., Mosczynska, A.
et al (1999) Differential alteration of phospholipase A2 activities in brains of patients with schizophrenia. Brain Research, 821, 407–413.
Scully, D., Kremer, J., Meade, M. M.
et al (1998) Physical exercise and psychological well-being: a critical review. British Journal of Sports Medicine, 32, 111–120.
Stoll, A. L., Severus, W. E., Freeman, M. P.
et al (1999) Omega-3 fatty acids in bipolar disorder: a preliminary double blind, placebo controlled trial. Archives of General Psychiatry, 56, 407–412.
Su, K. P., Shen, W. W. & Huang, S. Y. (2001) Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. European Neuropsychopharmacology, 11, 295–299.
Tanskanen, A., Hibbeln, J. R., Tuomilehto, J.
et al (2001) Fish consumption and depressive symptoms in the general population in Finland. Psychiatric Services, 52, 529–531.
Taylor, D., McConnell, H., Duncan-McConnell, D.
et al (2001) The South London and Maudsley NHS Trust 2001 Prescribing Guidelines. London: Martin Dunitz.
Ward, P. E., Sutherland, J., Glenn, E. M.
et al (1998) Niacin skin flush in schizophrenia: a preliminary report. Schizophrenia Research, 29, 269–274.
Warner, R., Laugharne, J., Peet, M.
et al (1999) Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. Biological Psychiatry, 45, 1138–1142.